Intramuscular Neridronate in Postmenopausal Women with Low Bone Mineral Density-Reference-Cited by-同舟云学术

Intramuscular Neridronate in Postmenopausal Women with Low Bone Mineral Density

Published:2008-10-23 Issue:5 Volume:83 Page:301-307
ISSN:0171-967X
Container-title:Calcified Tissue International
language:en
Short-container-title:Calcif Tissue Int

Author:

Adami Silvano,Gatti Davide,Bertoldo Francesco,Sartori Leonardo,Di Munno Ombretta,Filipponi Paolo,Marcocci Claudio,Frediani Bruno,Palummeri Ernesto,Fiore Carmelo Erio,Costi Daniele,Rossini Maurizio

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/s00223-008-9179-5.pdf

Reference22 articles.

1. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR, Fracture Intervention Trial (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial FIT Research Group. J Clin Endocrinol Metab 85:4118–4124

2. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY, Hip Intervention Program Study Group (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333–340

3. Chesnut CH III, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD (2004) Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249

4. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM (2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 54:1838–1846

5. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Meta-analysis on the Efficacy of Various Medicated Treatment Options for Osteoporosis;Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi;2023-09-26

2. The role of neridronate in the management of osteoporosis: A meta-analysis;Advances in Clinical and Experimental Medicine;2023-05-30

3. The Rationale for Using Neridronate in Musculoskeletal Disorders: From Metabolic Bone Diseases to Musculoskeletal Pain;International Journal of Molecular Sciences;2022-06-22

4. Monthly Intramuscular Neridronate for the Treatment of Postmenopausal Osteoporosis: Results of a 6-Year Prospective Italian Study;International Journal of Endocrinology;2019-02-06

5. Neridronate: From Experimental Data to Clinical Use;Clinical Medicine Insights: Therapeutics;2017-01